IL298518B2 - Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation - Google Patents
Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparationInfo
- Publication number
- IL298518B2 IL298518B2 IL298518A IL29851822A IL298518B2 IL 298518 B2 IL298518 B2 IL 298518B2 IL 298518 A IL298518 A IL 298518A IL 29851822 A IL29851822 A IL 29851822A IL 298518 B2 IL298518 B2 IL 298518B2
- Authority
- IL
- Israel
- Prior art keywords
- crystalline
- gdc
- imidazo
- oxooxazolidin
- dihydrobenzo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491812P | 2017-04-28 | 2017-04-28 | |
| PCT/EP2018/060820 WO2018197653A1 (en) | 2017-04-28 | 2018-04-26 | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL298518A IL298518A (en) | 2023-01-01 |
| IL298518B1 IL298518B1 (en) | 2025-01-01 |
| IL298518B2 true IL298518B2 (en) | 2025-05-01 |
Family
ID=62492573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298518A IL298518B2 (en) | 2017-04-28 | 2018-04-26 | Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation |
| IL317762A IL317762A (en) | 2017-04-28 | 2018-04-26 | Polymorphs and solid forms of (S)-2-((2-((S-4-(difluoromethyl)-2-oxoxazolidin-3-yl)-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepin-9-yl)amino)propanamide and methods of preparation |
| IL267464A IL267464B2 (en) | 2017-04-28 | 2019-06-18 | Polymorphs and solid forms of (s)-2-((2-((s-4-(difluoromethyl)-2-oxoxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][ 1,4]oxazepine-9-yl)amino)propanamide and methods of production |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317762A IL317762A (en) | 2017-04-28 | 2018-04-26 | Polymorphs and solid forms of (S)-2-((2-((S-4-(difluoromethyl)-2-oxoxazolidin-3-yl)-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepin-9-yl)amino)propanamide and methods of preparation |
| IL267464A IL267464B2 (en) | 2017-04-28 | 2019-06-18 | Polymorphs and solid forms of (s)-2-((2-((s-4-(difluoromethyl)-2-oxoxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][ 1,4]oxazepine-9-yl)amino)propanamide and methods of production |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20180339997A1 (https=) |
| EP (2) | EP4534148A3 (https=) |
| JP (2) | JP6998969B2 (https=) |
| KR (1) | KR102342776B1 (https=) |
| CN (1) | CN110650963B (https=) |
| AU (1) | AU2018259089B2 (https=) |
| CA (1) | CA3048591A1 (https=) |
| ES (1) | ES3027566T3 (https=) |
| IL (3) | IL298518B2 (https=) |
| MX (1) | MX394540B (https=) |
| PL (1) | PL3615541T3 (https=) |
| TW (1) | TWI826373B (https=) |
| WO (1) | WO2018197653A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016287463B2 (en) | 2015-07-02 | 2020-07-02 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2018109204A1 (en) | 2016-12-15 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
| ES3027566T3 (en) * | 2017-04-28 | 2025-06-16 | Hoffmann La Roche | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
| CN112313202A (zh) * | 2019-05-21 | 2021-02-02 | 江苏众强药业有限公司 | 曲前列尼尔钠盐新晶型及制备方法 |
| KR20220034129A (ko) * | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| TWI886177B (zh) * | 2019-11-25 | 2025-06-11 | 大陸商上海翰森生物醫藥科技有限公司 | 含三并環類衍生物的鹽或晶型及其醫藥組成物 |
| CN112830935B (zh) * | 2019-11-25 | 2023-12-22 | 上海翰森生物医药科技有限公司 | 含三并环类衍生物自由碱的晶型及其药物组合物 |
| TWI801730B (zh) * | 2020-04-07 | 2023-05-11 | 神雲科技股份有限公司 | 具系統設定資料同步功能的伺服器 |
| JP7625091B2 (ja) * | 2021-01-29 | 2025-01-31 | メッドシャイン ディスカバリー インコーポレイテッド | 三環式化合物及びその使用 |
| TW202440096A (zh) | 2023-03-24 | 2024-10-16 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| MY160064A (en) * | 2009-09-28 | 2017-02-15 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| KR20180093138A (ko) | 2013-12-16 | 2018-08-20 | 에프. 호프만-라 로슈 아게 | 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도 |
| AU2016287463B2 (en) | 2015-07-02 | 2020-07-02 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2018109204A1 (en) * | 2016-12-15 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
| ES3027566T3 (en) | 2017-04-28 | 2025-06-16 | Hoffmann La Roche | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
-
2018
- 2018-04-26 ES ES18728514T patent/ES3027566T3/es active Active
- 2018-04-26 WO PCT/EP2018/060820 patent/WO2018197653A1/en not_active Ceased
- 2018-04-26 IL IL298518A patent/IL298518B2/en unknown
- 2018-04-26 EP EP25158128.6A patent/EP4534148A3/en active Pending
- 2018-04-26 TW TW107114314A patent/TWI826373B/zh active
- 2018-04-26 MX MX2019012507A patent/MX394540B/es unknown
- 2018-04-26 IL IL317762A patent/IL317762A/en unknown
- 2018-04-26 PL PL18728514.3T patent/PL3615541T3/pl unknown
- 2018-04-26 JP JP2019558502A patent/JP6998969B2/ja active Active
- 2018-04-26 AU AU2018259089A patent/AU2018259089B2/en active Active
- 2018-04-26 KR KR1020197031575A patent/KR102342776B1/ko active Active
- 2018-04-26 CA CA3048591A patent/CA3048591A1/en active Pending
- 2018-04-26 CN CN201880028227.3A patent/CN110650963B/zh active Active
- 2018-04-26 US US15/963,876 patent/US20180339997A1/en not_active Abandoned
- 2018-04-26 EP EP18728514.3A patent/EP3615541B1/en active Active
-
2019
- 2019-06-18 IL IL267464A patent/IL267464B2/en unknown
-
2020
- 2020-05-15 US US16/875,545 patent/US11591345B2/en active Active
- 2020-05-15 US US16/875,537 patent/US11028100B2/en active Active
-
2021
- 2021-07-19 JP JP2021118355A patent/JP2021181446A/ja active Pending
-
2023
- 2023-01-26 US US18/101,951 patent/US12410189B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12410189B2 (en) | Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production | |
| CA2900322C (en) | Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one | |
| AU2018372180B2 (en) | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production | |
| JP2018080179A (ja) | ２−（４−（２−（１−イソプロピル−３−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）−５，６−ジヒドロベンゾ［ｆ］イミダゾ［１，２−ｄ］［１，４］オキサゼピン−９−イル）−１Ｈ−ピラゾール−１−イル）−２−メチルプロパンアミドの多形、それらの生成方法及び薬学的使用 | |
| HK40124018A (en) | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | |
| BR112019013292B1 (pt) | Polimorfos anidratos cristalinos, polimorfo triidrato cristalino, composições farmacêuticas, processo para preparar um polimorfo cristalino e uso de um polimorfo cristalino | |
| HK40020487A (en) | Polymorphs and solid forms of gdc-0077, and methods of production thereof | |
| HK40020487B (en) | Polymorphs and solid forms of gdc-0077, and methods of production thereof | |
| HK1223101B (zh) | Gdc-0032的多晶型物、其制备方法和药物用途 | |
| HK40003818A (en) | Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof |